▲May 15-16New Drug Innovators SummitScan to Register
Note:This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position. Reposting of this article requires authorization.
In the biopharmaceutical field, cell and gene therapy (CGT) has become a cutting-edge battleground for major pharmaceutical companies due to its innovative treatment concepts and significant therapeutic potential. In 2024, facing the challenges of technological breakthroughs, market competition pressures, and changes in the capital environment, large pharmaceutical enterprises are continuously making strategic moves in the CGT therapy sector. Let’s take a look:Roche: Increase R&D Investment, Broaden Product Line
Roche Continues to Increase R&D Investment in CGT Therapies in 2024Novartis: Deepening Strengths, Advancing Commercialization
Novartis has long been invested in the CGT therapy field and will continue to deepen its focus on key projects in 2024.For already marketed gene therapy products, such as Zolgensma for spinal muscular atrophy (SMA), Novartis has increased market promotion efforts to improve the product's accessibility.At the same time, Novartis is actively conducting clinical trials to explore the potential applications of Zolgensma in other related disease areas.In the field of cell therapy, Novartis is continuously optimizing the manufacturing process of CAR-T cell therapy, reducing costs, and improving treatment outcomes.By collaborating with medical institutions and insurance companies, Novartis is actively promoting the commercialization of CGT therapies to benefit more patients.Pfizer: Strengthening Collaborative Innovation, Expanding Business Horizons
Pfizer Strengthens Its Position in CGT Therapy Field Through a Series of Collaborations in 2024
Chinese Pharmaceutical Companies: Catching Up with International Standards, Focusing on Distinctive Development
Some large pharmaceutical companies in China, such as Hengrui Pharma,Fosun PharmaceuticalIn 2024, significant efforts were also made to actively expand into the CGT therapy field. Hengrui Pharma increased its R&D investment, established a professional CGT R&D team, and focused on the field of cancer cell therapy, initiating multiple clinical trials for CAR-T cell therapy and TCR-T cell therapy. Fosun Pharmaceutical, on the other hand, collaborated with internationally renowned pharmaceutical companies to introduce advanced CGT technologies and products, accelerating its development in this area. Meanwhile, Fosun Pharmaceutical also emphasized the expansion of the domestic market, promoting the commercialization of already marketed CGT products and increasing their market share.The layout of major pharmaceutical companies in the CGT therapy field in 2024 fully demonstrates the important strategic position and enormous development potential of this field. Despite facing multiple challenges in technology, market, and capital, pharmaceutical companies have injected strong momentum into the development of CGT therapies through increased R&D investment, enhanced cooperative innovation, and the promotion of commercialization processes. Looking ahead, with continuous technological breakthroughs and the gradual expansion of clinical applications, CGT therapies are expected to achieve significant advancements in more disease treatment areas.References: Publicly available information
Copyright statement: This article is reproduced from the Biopharmaceutical Era，Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
Click the image to register
